Fastest Growing Healthcare Stocks in February 2022

One of the largest and most complex industries, the healthcare industry consists of a wide array of companies selling medical products and services. The healthcare industry includes companies that sell drugs, medical devices, and insurance, as well as hospitals and healthcare providers. Some of the world's largest healthcare companies include UnitedHealth Group Inc. (UNH), Pfizer Inc. (PFE) and AbbVie Inc. (ABBV) exists. The healthcare industry has caught the attention of investors as some of these companies have received approvals for drugs to treat Covid-19 and have begun distributing vaccines. While some companies are rushing to develop their own Covid-19 drugs and get approval, others are supplying products to test and manage the treatment of the virus. Despite this, healthcare stocks represented by the exchange-traded fund (ETF), Health Care Select Sector SPDR ETF (XLV), underperformed in the broader market. Health stocks reported an overall return of 12%.

Fastest Growing Healthcare Stocks

They are ranked according to a growth model that scores companies with equal weight percent increase in revenue and earnings per share in the last quarter of the year. Both sales and earnings are critical factors in a company's success. Therefore, ranking companies by only one growth metric makes a ranking susceptible to that quarter's accounting anomalies, which may render one number or the other un-representative of the business overall.

	Price ($)	Market Cap ($B)	EPS Growth (%)	Revenue Growth (%)
Pfizer Inc. (PFE)	54,05	303,4	446,2	134,4
Royalty Pharma PLC (RPRX)	39,31	16,8	1,1	8,6
Qiagen NV (QGEN)	49,57	11,3	714,3	10,5

  Pfizer Inc.: Pfizer is a global pharmaceutical company. It develops, manufactures and sells a variety of biopharmaceutical products, including drugs and vaccines. On January 10, 2022, Pfizer signed an agreement with Acuitas Therapeutics, which develops delivery systems for mRNA-based therapeutics. Under the agreement, Pfizer will be able to license Acuitas' lipid nanoparticle (LNP) delivery technology for vaccine and development purposes. Royalty Pharma PLC: Royalty Pharma generates revenue by purchasing biopharmaceutical royalties. It partners with other companies to help fund late-stage clinical trials and new product launches in exchange for future royalties. In January 2022, the company announced that it would provide long-term capital to Cytokinetics Inc. (CYTK) to support two drugs that treat heart conditions. Qiagen NV: Qiagen is a Netherlands-based company serving customers in areas such as cancer therapy, instrumentation, genomics and next-generation sequencing. The company's areas of expertise include using sample and assay technologies, bioinformatics and automation systems to isolate and prepare DNA, RNA and proteins, among other materials.